Codexis (CDXS)
(Delayed Data from NSDQ)
$3.15 USD
+0.18 (6.06%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.13 -0.02 (-0.63%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.15 USD
+0.18 (6.06%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.13 -0.02 (-0.63%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Zacks News
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Codexis (CDXS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis (CDXS) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study
by Zacks Equity Research
BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.
What Makes Codexis (CDXS) a New Strong Buy Stock
by Zacks Equity Research
Codexis (CDXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Synthetic Biology Stocks in Focus With Strong Potential
by Indrajit Bandyopadhyay
Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.
Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 133.33% and 27.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Could Help Codexis (CDXS) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Codexis (CDXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Codexis (CDXS) Surges 12.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 58.82% and 41.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
by Zacks Equity Research
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.
Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca (AZN) Q2 Earnings In Line, Vaccine Aids Sales
by Zacks Equity Research
AstraZeneca (AZN) surpasses second-quarter estimates for revenues while earnings meet estimates. Stock up in pre-market.
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe
by Zacks Equity Research
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
by Zacks Equity Research
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
Strength Seen in Codexis (CDXS): Can Its 12.6% Jump Turn into More Strength?
by Zacks Equity Research
Codexis (CDXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 30.00% and 21.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 37.50% and 22.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Codexis (CDXS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Mar 2, 2020
by Zacks Equity Research
Companies in the news are: ALT, BIG, W, CDXS
Codexis (CDXS) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of -66.67% and -11.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).